双膦酸盐临床应用风险因素的研究进展

The Research Progress on Clinical Application Risk Factors of Bisphosphonates

目的随着强效抗骨吸收药物双膦酸盐(BPs)的引入,骨质疏松(OP)的临床治疗取得了很大进展。BPs是美国骨与矿物质研究学会(ASBMR)推荐长期使用抗OP的药物之一,但长期使用BPs给患者带来的风险因素却又不容忽视。其中较突出的风险因素包括:非典型股骨骨折、颌骨坏死及房颤。如何应对这些风险因素才可使BPs应用于临床上的益处获得最大化,值得我们深思和探讨。

With the emergence of bisphosphonates（ BPs）,which is a strong anti-bone absorption drug,the clinical treatment of osteoporosis（ OP） has been largely improved. BPs is one of the drugs recommended for long-term use by the American society for bone and mineral research（ ASBMR）,but the risk of adverse events associated with long-term BPs therapy,such as atypical femoral fracture,osteonecrosis of the jaws and atrial fibrillation,should not be ignored. How to manage these adverse events and maximize the clinical benefits of BPs needs further study.